title: Muscle CARs and TcRs: turbo-charged technologies for the (T cell) masses.
abstract: A central role for T cells in the control of cancer has been supported by both animal models and clinical observations. Accordingly, the development of potent anti-tumor T cell immunity has been a long-standing objective of immunotherapy. Emerging data from clinical trials that test T cell immune-modulatory agents and genetically engineered and re-targeted T cells have begun to realize the profound potential of T cell immunotherapy to target cancer. This review will focus on a description of recent conceptual and technological advances for the genetic engineering of T cells to enhance anti-tumor T cell immunity through the introduction of tumor-specific receptors, both Chimeric Antigen Receptors (CAR) and T cell receptors (TcR), as well as an overview of emerging data from ongoing clinical trials that highlight the potential of these approaches to effect dramatic and potent anti-tumor immunity.
authors: Department of Pathology and Laboratory Medicine, Perelman School of Medicine, Abramson Family Cancer Research Institute, University of Pennsylvania, 422 Curie Boulevard, 409-C Stellar-Chance Laboratories, Philadelphia, PA 19104-4283, USA. Michael.kalos@uphs.upenn.edu
authors: Michael
authors: M
authors: Kalos
mesh_terms: D000818:Animals; D005818:Genetic Engineering; D006801:Humans; D007167:Immunotherapy; D011948:Receptors, Antigen, T-Cell / Q000235:genetics / Q000276:immunology*; D013601:T-Lymphocytes / Q000276:immunology*
chemical_list: D011948:Receptors, Antigen, T-Cell